Matt Healy holds leadership roles across the Clinical Operations, Project Management and Pharmacovigilance functional areas at Rho.  Mr. Healy has extensive expertise in strategy development and management of complex North American and global CNS centered trials.

Throughout his career, Mr. Healy has led or supported the execution of various Phase 2 through 4 programs focused on the following indications; Alzheimer’s Disease, Vascular Dementia, Migraine, Late-Life Depression, Geriatric Schizophrenia and Traumatic Brain injury. In association with these indications, Mr. Healy is experienced in the administration and interpretation of cognitive screening and assessment measures for these populations.

Mr. Healy received his undergraduate degree from the Catholic University of America and his graduate degree in Clinical Rehabilitation and Mental Health Counseling with a concentration in Neuropsychology from the University of Pittsburgh.

Why Clinical Research?

“During my time in graduate school, I had my first exposure to study coordination for both academic and industry-sponsored clinical trials. My initial role was administering a battery of cognitive tests to patients with AD, TBI, and Depression. But what intrigued me the most was being able to see first-hand how some of these investigational therapies were altering the course of these patients’ lives. I feel fortunate to have been able to have that experience at a young age, as it has informed what has turned into a long career in the clinical research industry.”

This is what drives Matt:

“There are multiple aspects of my work that drives my motivation and commitment. One of these is the constant opportunity to refine and improve processes around clinical trial execution. At a time when so much of the industry is in a rapid change mode, it is exciting to participate in that direction of change at Rho. Another aspect of my work that drives me is being able to exercise creativity and work to adopt solutions that will drive how our industry adapts to a more patient-centric, virtual-trial environment. And simple knowing that the work we do has a direct impact on improving patient health and quality of life … that is the ultimate motivation.”